News - Nexavar


Current filters:


Popular Filters

19 to 33 of 33 results

Indian hearings on Bayer Nexavar compulsory license delayed


India's Intellectual Property Appellate Board (IPAB) in Chennai has postponed hearing the appeal by German…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Adding Tarceva to Nexavar no better than Nexavar alone for liver cancer


A Phase III trial evaluating the efficacy and safety of the addition of Roche's Tarceva (erlotinib) tablets…

Astellas PharmaBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchTarceva

Bristol-Myers brivanib fails in Ph III liver cancer trial


US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday reported results of the Phase III BRISK-FL clinical…

Bristol-Myers SquibbbrivanibNexavarOncologyPharmaceuticalResearch

Bayer and Onyx' Nexavar fails in Ph III lung cancer study


There was disappointment for German drug major Bayer (BAYB: DE) and partner Onyx Pharmaceuticals (Nasdaq:…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Pfizer's Torisel fails in Ph III advanced renal cell cancer study


There was disappointment for global pharma behemoth Pfizer (NYSE: PFE) when it said that the Phase III…

BayerNephrology and HepatologyNexavarOncologyPfizerPharmaceuticalResearchTorisel

Bayer challenges Indian ruling on Nexavar patent


German drug major Bayer (BAYN: DE) has launched an appeal against the Indian Patent Office, which a couple…


Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too


Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

Reimbursement and/or budget-related factors restrict use of angiogenesis inhibitor in Brazil and Mexico; Study


Depending on the tumor type, around one-quarter to one-third of surveyed Brazilian and Mexican oncologists'…

AvastinMarkets & MarketingNexavarOncologyPharmaceuticalPricingSouth AmericaSutent

India issues compulsory license for Bayer cancer drug Nexavar


The Indian Patent Office has issued the first-ever compulsory licence in India to a generic drug manufacturer.…

Asia-PacificBayerGenericsNatco PharmaNexavarOncologyPatentsPharmaceutical

Three “targeted” cancer drugs slightly raise fatal side effects risk, says Dana-Faber Inst


2 Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated…


Bayer settles with Onyx over Nexavar and regorafenib with $160 million payment


US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) and German pharma major Bayer HealthCare, a unit of…

BayerLegalLicensingNexavarOncologyOnyx PharmaceuticalsPharmaceuticalregorafenib

Roundup of upcoming cancer drug trials to be presented at ASCO


A number of leading pharmaceutical companies – include Pfizer, Bayer, Roche and AstraZeneca - have…


Low-dose sorafenib may improve therapy for head and neck cancer, Ohio researchers find


Adding low doses of the targeted agent sorafenib (German drug major Bayer and Onyx’ kidney and liver…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

19 to 33 of 33 results

Back to top